Previous 10 | Next 10 |
Biotechs struggled in 2021 as indexes lagged the broader market. So far in 2022, biotechs have dropped sharply as interest rate uncertainty has created a risk-off market. A rising interest rate environment remains the biggest risk for biotechs. With the S&P 500 biotech index h...
Potential Deal in the Works, Citrix Systems to be acquired by Vista and Elliott. Vista and Evergreen (an affiliate of Elliott) intend to combine Citrix and TIBCO Software, one of Vista’s portfolio companies. Cedar Fair (FUN) received an unsolicited non-binding proposal from...
Pfizer (NYSE:PFE) is scheduled to announce Q4 earnings results on Tuesday, February 8th, before market open. The consensus EPS Estimate is $0.87 (+107.1% Y/Y) and the consensus Revenue Estimate is $24.2B (+107.2% Y/Y). Over the last 2 years, PFE has beaten EPS estimates 75% of the time and ha...
If you believe in the January Barometer theory -- that returns in the first month of the year are a bellwether for performance for the rest of the year -- then biotech investors better buckle their seatbelts. The iShares Nasdaq Biotechnology ETF (IBB +1.2%) finished off last month with a ...
NEW YORK, NY / ACCESSWIRE / December 31, 2021 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to Pfizer Inc. for $100.00 per share in cash is fair to Arena shareholders. Halper Sadeh encourages Arena share...
Potential deal in the works - Cerner to be acquired by Oracle in mega tech deal. The acquisition of Cerner by Oracle could be a net negative for Oracle shareholders considering how challenging the integration of the company is likely to be. The size of the deal ($28.4 billion incl...
The acquisition of Arena Pharmaceuticals by Pfizer for $4.69 billion. The announcement to acquire Arena comes less than a month after Pfizer closed another $2.2 billion deal. Bottomline Technologies (EPAY), a potential deal in the works, signed a merger agreement with Thoma Bravo....
Arena Pharmaceuticals (NASDAQ:ARNA) to grant its 16 new employees 28,659 inducement restricted stock units ("RSUs"). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary ...
Pfizer (NYSE:PFE) says that 5-year follow-up data on Vyndaqel (tafamidis meglumine)/Vyndamax (tafamidis) showed that the drug provides a strong survival benefit over five years for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Results were based on an analysis of a phase 3 tri...
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...